论文部分内容阅读
目的探讨匹多莫德联合孟鲁司特哮喘患儿免疫功能及肺功能的影响。方法选择鄢陵县人民医院2015年7月至2016年7月收治的小儿支气管哮喘患儿96例,按照双盲法分为观察组和对照组各48例。对照组给予匹多莫德治疗,观察组在对照组的基础上联合使用孟鲁司特治疗。观察两组患儿治疗前后肺功能及免疫功能变化情况。结果两组患儿治疗后Ig A、Ig M及Ig G水平均有所上升,观察组分别为(7.32±1.34)、(7.08±1.64)、(11.32±1.91)g/L,显著优于对照组;肺功能改善方面,观察组也明显好于对照组(P<0.05)。结论匹多莫德联合孟鲁司特治疗小儿支气管哮喘效果显著,能明显改善患儿呼吸功能,还能提高机体的免疫功能,值得临床推广。
Objective To investigate the effects of pidotimod on the immune function and pulmonary function in children with montelukast asthma. Methods Ninety-six children with bronchial asthma were selected from Yanling County People’s Hospital from July 2015 to July 2016, and divided into observation group and control group according to double-blind method. The control group was treated with pidotimod. The observation group was treated with montelukast on the basis of the control group. The changes of pulmonary function and immune function in two groups before and after treatment were observed. Results The levels of Ig A, Ig M and Ig G in the two groups increased after treatment (7.32 ± 1.34, 7.08 ± 1.64, and (11.32 ± 1.91) g / L, respectively, which were significantly better than those of the control Group; lung function improvement, the observation group was also significantly better than the control group (P <0.05). Conclusion Pidotimod montelukast treatment of children with bronchial asthma significantly, can significantly improve children’s respiratory function, but also improve the body’s immune function, is worth clinical promotion.